Mira Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage biopharmaceutical company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three primary product candidates: Ketamir-2, an oral ketamine analog designed as a low-affinity NMDA receptor antagonist for neuropathic and inflammatory pain; MIRA-55, a novel synthetic cannabinoid targeting neuropathic pain and anxiety without the typical cognitive side effects of THC; and SKNY-1, a candidate targeting obesity and nicotine addiction acquired through the acquisition of SKNY Pharmaceuticals in September 2025.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing Ketamir-2, a next-generation oral NMDA receptor modulator, into mid-stage clinical trials for neuropathic pain (specifically chemotherapy-induced peripheral neuropathy) and treatment-resistant depression.
Expected impact: Demonstrate early clinical efficacy and establish proof-of-concept, enhancing the asset's licensing and partnership value.
Securing worldwide exclusive development, commercialization, sublicensing, and IP enforcement rights for MIRA-55 and SKNY-1 through an amended agreement with MIRALOGX LLC.
Expected impact: Establishes a clean, unified global rights structure across the entire pipeline, strengthening MIRA's position with potential partners and investors.
Integrating SKNY-1, a novel oral therapeutic targeting obesity and nicotine addiction, into the development pipeline following the acquisition of SKNY Pharmaceuticals.
Expected impact: Diversifies MIRA's risk profile beyond pure CNS indications into the high-growth metabolic and addiction markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To expand MIRA's pipeline into the multi-billion dollar obesity and nicotine addiction markets with SKNY-1, while strengthening MIRA's balance sheet through a $5 million capital contribution in marketable securities.
Financial impact: Contributed $5 million in marketable securities at closing, helping MIRA temporarily regain compliance with Nasdaq's minimum stockholders' equity requirement.
Strategic Partnerships
Consolidates global intellectual property, sublicensing, and enforcement rights for MIRA-55 and SKNY-1, giving MIRA complete control over the development and commercialization pathways of its entire pipeline.
Terms: The amended agreement does not materially modify the previously disclosed core economic terms of the existing license arrangements.